Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Monahan

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
Gene Therapy|February 19, 2000
AAV vectors: is clinical success on the horizon?P E Monahan, R J Samulski
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant factor IX for clinical and research usePaul E Monahan, Jorge Di Paola
Molecular Medicine Today|November 14, 2000
Adeno-associated virus vectors for gene therapy: more pros than cons?P E Monahan, R J Samulski
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 15, 2009
Familial deficiency of vitamin K-dependent clotting factorsB W Weston, P E Monahan
The New England Journal of Medicine|May 17, 2023
Long-Term Effects of Hemophilia B Gene Therapy. ReplySteven W Pipe, Paul E Monahan
Current Gene Therapy|December 20, 2003
Evaluation of risks related to the use of adeno-associated virus-based vectorsL Tenenbaum, E Lehtonen, P E Monahan
Blood|February 25, 2005
A classification system for cross-reactive material-negative factor XI deficiencyDmitri V Kravtsov, Paul E Monahan, David Gailani
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Journal of Environmental Radioactivity|March 31, 2022
The effectiveness of passive sumps and static cowls in reducing radon levels in new build Irish dwellingsE Monahan, P Murphy, S Long, et al.
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
Gene Therapy|February 19, 2000
AAV vectors: is clinical success on the horizon?P E Monahan, R J Samulski
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant factor IX for clinical and research usePaul E Monahan, Jorge Di Paola
Molecular Medicine Today|November 14, 2000
Adeno-associated virus vectors for gene therapy: more pros than cons?P E Monahan, R J Samulski
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 15, 2009
Familial deficiency of vitamin K-dependent clotting factorsB W Weston, P E Monahan
The New England Journal of Medicine|May 17, 2023
Long-Term Effects of Hemophilia B Gene Therapy. ReplySteven W Pipe, Paul E Monahan
Current Gene Therapy|December 20, 2003
Evaluation of risks related to the use of adeno-associated virus-based vectorsL Tenenbaum, E Lehtonen, P E Monahan
Blood|February 25, 2005
A classification system for cross-reactive material-negative factor XI deficiencyDmitri V Kravtsov, Paul E Monahan, David Gailani
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Journal of Environmental Radioactivity|March 31, 2022
The effectiveness of passive sumps and static cowls in reducing radon levels in new build Irish dwellingsE Monahan, P Murphy, S Long, et al.
Pageof 13